U.S. FDA clears Optovue OCT angiography measurement technology

June 13, 2018
The optical coherence tomography angiography blood vessel measurement technology helps clinicians manage diseases that cause progressive blindness.

Optovue (Fremont, CA) has received U.S. FDA clearance of its AngioAnalytics optical coherence tomography angiography (OCTA) blood vessel measurement technology to help clinicians manage diseases that cause progressive blindness. The company also received clearance for its three-dimensional projection artifact removal (3D PAR) software, which improves OCTA image quality and enables accurate measurement and interpretation of OCTA images. AngioAnalytics and 3D PAR are commercially available in the U.S.

Related: Optovue develops higher-density OCT angiography system for ophthalmology

AngioAnalytics brings objective data and analysis to the company's commercially available AngioVue OCTA technology that provides high-resolution imaging of retinal blood vessels. Combined, the two technologies create color-encoded maps of the vessel densities of the retina or optic nerve, and provide analyses of areas where there is blood vessel loss (non-perfusion), abnormal blood vessel growth (flow area), and several parameters to assess change to the foveal avascular zone, an area of the retina profoundly affected by diabetic retinopathy. The AngioAnalytics software also provides trend analysis so that physicians can objectively monitor retinal and vascular changes caused by disease progression or from treatment.

Projection artifacts, inherent in OCTA technology from all manufacturers, occur when ghost images of blood vessels that exist in one retinal layer are projected onto other layers. The shadows from these vessels make it difficult to accurately interpret whether, and how much, abnormal vessel growth is actually present in the specific layers. 3D PAR technology is important for improving OCTA image quality, as it forms the basis for accurate qualitative image interpretation and reliable measurements that enable physicians to quickly document disease states and incorporate OCTA technology into their diagnostic armamentarium.

For more information, please visit www.optovue.com.

About the Author

BioOptics World Editors

We edited the content of this article, which was contributed by outside sources, to fit our style and substance requirements. (Editor’s Note: BioOptics World has folded as a brand and is now part of Laser Focus World, effective in 2022.)

Sponsored Recommendations

Photonics Business Moves: December 1, 2023

Dec. 1, 2023
Here are the top four photonics business moves that made headlines during the week ending December 1, 2023.

Video: December 1, 2023 Photonics Hot List

Dec. 1, 2023
In this episode, we cover how laser scanning aids advanced robotics, ultrafast lasers on the tip of a finger, and a tunable laser that controls material functionality.

Next generation tunable infrared lasers

Nov. 28, 2023
Discussion of more powerful and stable quantum cascade tunable infrared lasers, applications, and test results.

What AI demands mean for data centers

Nov. 28, 2023
The 2023 Photonics-Enabled Cloud Computing Summit assembled by Optica took an aggressive approach to calling out the limitations of today’s current technologies.

Voice your opinion!

To join the conversation, and become an exclusive member of Laser Focus World, create an account today!